ME02341B - Nova antitijela za inhibiciju c-met dimerizacije i njihova upotreba - Google Patents
Nova antitijela za inhibiciju c-met dimerizacije i njihova upotrebaInfo
- Publication number
- ME02341B ME02341B MEP-2016-197A MEP19716A ME02341B ME 02341 B ME02341 B ME 02341B ME P19716 A MEP19716 A ME P19716A ME 02341 B ME02341 B ME 02341B
- Authority
- ME
- Montenegro
- Prior art keywords
- antibody
- met
- bivalent
- cdr
- seq
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004408 hybridoma Anatomy 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 241001529936 Murinae Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000009452 underexpressoin Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
Claims (22)
1. Izolovano antitelo, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, naznačen time što antitelo sadrži težak lanac koji sadrži CDR-H1, CDR-H2 i CDR-H3 koji sadrži, respektivno, aminokiselinsku sekvencu SEQ ID Nos. 1, 2 i 3; i lak lanac koji sadrži CDR-L1, CDR-L2 i CDR-L3 koji sadrži, respektivno, aminokiselinsku sekvencu SEQ ID Nos. 10,11 i 12.
2. Antitelo iz zahteva 1, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, naznačen time što sadrži težak lanac koji sadrži aminokiselinsku sekvencu SEQ ID No. 18 i lak lanac koji sadrži aminokiselinsku sekvencu SEQ ID No. 21.
3. Mišji hibridom sposoban da luči antitelo kao što se zahteva u zahtevu 2, naznačen time što je navedeni hibridom mišji hibridom deponovan u CNCM, Institut Pasteur, Paris, 14. marta, 2007. pod brojem I-3731.
4. Antitelo iz zahteva 1 ili 2, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c- Met, naznačen time što je navedeno antitelo monoklonsko antitelo.
5. Antitelo iz zahteva 4, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, naznačen time što je navedeno antitelo himerno antitelo, gde su konstantni regioni lakog lanca i teškog lanca izvedeni iz humanog antitela.
6. Antitelo iz jednog od zahteva 1 do 5, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, naznačen time što je sposoban da specifično veže c-Met.
7. Antitelo iz zahteva 6, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, naznačen time što je sposoban da inhibira aktivaciju c-Met zavisnu od liganda i nezavisnu od liganda.
8. Antitelo iz zahteva 7, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, naznačen time što inhibira dimerizaciju c-Met.
9. Izolovana nukleinska kiselina, naznačena time što je odabrana od sledećih nukleinskih kiselina: a) nukleinska kiselina, DNK ili RNK, koja kodira antitelo, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, kao što se zahteva u jednom od zahteva 1 i 2; b) nukleinska kiselina koja sadrži sekvencu DNK koja sadrži CDR-H1 sekvencu SEQ ID No. 24, CDR-H2 sekvencu SEQ ID No. 25, CDR-H3 sekvencu SEQ ID No. 26 i CDR-L1 sekvencu SEQ ID No. 33, CDR-L2 sekvencu SEQ ID No. 34 i CDR-L3 sekvencu SEQ ID No. 35; c) nukleinska kiselina koja sadrži sekvencu DNK koja sadrži sekvencu teškog lanca SEQ ID No. 41 i sekvencu lakog lanca SEQ ID No. 44; d) RNK nukleinske kiseline koje odgovaraju nukleinskim kiselinama kao što su definisane u b) i/ili c); i e) nukleinske kiseline komplementarne nukleinskim kiselinama kao što su definisane u a), b) i c).
10. Vektor koji sadrži nukleinsku kiselinu kao što se zahteva u zahtevu 9.
11. Ćelija domaćin koja sadrži vektor kao što se zahteva u zahtevu 10.
12. Metod za proizvodnju antitela, ili jednog od njegovih dvovalentnih fragmenata za vezivanje c-Met, kao što se zahteva u jednom od zahteva 1, 2 i 4-8, naznačen time što metod sadrži: a) gajenje ćelije domaćina kao što se zahteva u zahtevu 11, u medijumu i u odgovarajućim uslovima za kulturu ; i b) sakupljanje navedenih antitela, ili jednog od njihovih dvovalentnih fragmenata za vezivanje c-Met, iz medijuma za kulturu ili navedenih gajenih ćelija.
13. Antitelo ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, iz zahteva 1, 2, i 4-8 ili dobijen metodom iz zahteva 12, za upotrebu kao lek.
14. Sastav koji sadrži kao aktivan sastojak jedinjenje koje se sastoji od antitela ili jednog od njihovih dvovalentnih fragmenata za vezivanje c-Met, kao što se zahteva u jednom od zahteva 1, 2, i 4-8, ili dobijen metodom iz zahteva 12, ili proizveden pomoću hibridoma prema zahtevu 3.
15. Sastav prema zahtevu 14, naznačen time što dalje sadrži jedno sredstvo kao kombinovani proizvod za simultanu, odvojenu ili sukcesivnu upotrebu, i gde je navedeno sredstvo anti-tumorsko antitelo.
16. Sastav prema zahtevima 14 ili 15, naznačen time što dalje sadrži bar jedno sredstvo kao kombinovani proizvod za simultanu, odvojenu ili sukcesivnu upotrebu, gde je navedeno sredstvo citotoksično/citostatičko sredstvo.
17. Sastav prema jednom od zahteva 14 do 16, naznačen time što bar jedno od navedenih antitela, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, spregnut sa ćelijskim toksinom i/ili radioaktivnim elementom.
18. Sastav prema jednom od zahteva 14 do 17 za upotrebu kao lek.
19. Upotreba antitela ili jednog od njegovih dvovalentnih fragmenata za vezivanje c-Met, iz zahteva 1, 2, i 4-8, ili dobijog metodom iz zahteva 12, ili proizvedenog pomoću hibridoma prema zahtevu 3; ili sastava iz jednog od zahteva 14 do 17 za dobijanje leka za sprečavanje ili za lečenje kancera.
20. Upotreba prema zahtevu 19, naznačena time što je navedeni kancer kancer odabran od kancera prostate, osteosarkoma, kancera pluća, kancera dojke, endometrijumskog kancera, glioblastoma ili kancera kolona.
21. Upotreba prema zahtevu 19 ili 20, naznačena time što je navedeni kancer kancer povezan sa aktivacijom c-Met, odabran od kancera koji su zavisni i/ili nezavisni od HGF.
22. Metod in vitro dijagnoze oboljenja indukovanih prekomernom ekspresijom ili nedovoljnom ekspresijom c-Met receptora, koji počinje od biološkog uzorka u kome se sumnja na abnormalno prisustvo c-Met receptora, naznačen time što navedeni metod sadrži korak u kom se navedeni biološki uzorak dovodi u dodir sa antitelom ili jednim od njegovih dvovalentnih fragmenata za vezivanje c-Met, iz zahteva 1, 2, i 4-8, ili dobijenim metodom iz zahteva 12, ili proizvedenim pomoću hibridoma prema zahtevu 3, gde je moguće da se navedeno antitelo, ako je potrebno, obeleži.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92978907P | 2007-07-12 | 2007-07-12 | |
| EP07301231A EP2014681A1 (en) | 2007-07-12 | 2007-07-12 | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US2063908P | 2008-01-11 | 2008-01-11 | |
| EP08786050.8A EP2188312B1 (en) | 2007-07-12 | 2008-07-10 | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| PCT/EP2008/059026 WO2009007427A2 (en) | 2007-07-12 | 2008-07-10 | Novel antibodies inhibiting c-met dimerization, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02341B true ME02341B (me) | 2015-12-31 |
Family
ID=38871713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-197A ME02341B (me) | 2007-07-12 | 2008-07-10 | Nova antitijela za inhibiciju c-met dimerizacije i njihova upotreba |
Country Status (35)
| Country | Link |
|---|---|
| US (6) | US8329173B2 (me) |
| EP (6) | EP2014681A1 (me) |
| JP (4) | JP5562844B2 (me) |
| KR (4) | KR101625234B1 (me) |
| CN (4) | CN103509112B (me) |
| AR (4) | AR067517A1 (me) |
| AU (1) | AU2008274171B2 (me) |
| BR (1) | BRPI0815564B8 (me) |
| CA (4) | CA2888691C (me) |
| CL (1) | CL2008002015A1 (me) |
| CO (1) | CO6170364A2 (me) |
| CY (1) | CY1116608T1 (me) |
| DK (1) | DK2188312T3 (me) |
| ES (5) | ES2693542T3 (me) |
| HR (1) | HRP20150887T1 (me) |
| HU (1) | HUE026026T2 (me) |
| IL (5) | IL203114A (me) |
| MA (1) | MA31977B1 (me) |
| ME (1) | ME02341B (me) |
| MX (3) | MX345391B (me) |
| MY (1) | MY158756A (me) |
| NZ (4) | NZ599958A (me) |
| PA (1) | PA8789201A1 (me) |
| PH (3) | PH12018502039A1 (me) |
| PL (1) | PL2188312T3 (me) |
| PT (1) | PT2188312E (me) |
| RS (1) | RS54197B1 (me) |
| RU (1) | RU2552161C2 (me) |
| SA (1) | SA08290423B1 (me) |
| SG (1) | SG183015A1 (me) |
| SI (1) | SI2188312T1 (me) |
| TN (1) | TN2010000016A1 (me) |
| TW (4) | TWI592427B (me) |
| WO (1) | WO2009007427A2 (me) |
| ZA (1) | ZA201000966B (me) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| US20140112911A9 (en) * | 2008-12-02 | 2014-04-24 | Liliane Goetsch | Novel anti-cmet antibody |
| MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
| JP5497887B2 (ja) | 2009-04-07 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異性抗ＥｒｂＢ−２／抗ｃ−Ｍｅｔ抗体 |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| KR101671378B1 (ko) * | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도 |
| KR101748707B1 (ko) | 2009-11-27 | 2017-06-20 | 삼성전자주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트 |
| EP3511342B1 (en) * | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| EP2808344A1 (en) * | 2010-06-01 | 2014-12-03 | Monash University | Antibodies directed to the receptor tyrosine kinase c-Met |
| EP2402370A1 (en) | 2010-06-29 | 2012-01-04 | Pierre Fabre Médicament | Novel antibody for the diagnosis and/or prognosis of cancer |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| AU2011295919A1 (en) | 2010-08-31 | 2013-03-07 | Genentech, Inc. | Biomarkers and methods of treatment |
| RU2013114783A (ru) * | 2010-09-03 | 2014-10-10 | Академиа Синика | Anti-с-мет антитела и способы их применения |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| BR122014027420A2 (pt) | 2010-11-03 | 2019-08-20 | Argenx Bvba | Anticorpos anti c-met |
| EP2853542A1 (en) | 2010-11-24 | 2015-04-01 | Glaxo Group Limited | Multispecific antigen binding proteins targeting HGF |
| KR101444837B1 (ko) | 2011-06-03 | 2014-09-30 | 한국생명공학연구원 | ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도 |
| DK2723769T4 (da) * | 2011-06-23 | 2022-09-05 | Ablynx Nv | Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner |
| EP3466972A1 (en) | 2011-06-23 | 2019-04-10 | Ablynx NV | Serum albumin binding proteins |
| US20130004484A1 (en) * | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| KR20140064971A (ko) | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| WO2013043452A1 (en) | 2011-09-20 | 2013-03-28 | Eli Lilly And Company | Anti-c-met antibodies |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| CN103889451B (zh) * | 2011-09-30 | 2016-06-29 | 埃博灵克斯股份有限公司 | 与C-Met相关的生物物质 |
| KR20130037153A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| KR101865223B1 (ko) * | 2011-10-05 | 2018-06-08 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도 |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| EP2773660A2 (en) | 2011-11-03 | 2014-09-10 | Argen-X B.V. | Chimeric human-camel antigens and their use |
| BR112014012005A2 (pt) | 2011-11-21 | 2017-12-19 | Genentech Inc | composições, métodos, formulação farmacêutica e artigo |
| WO2013079973A1 (en) | 2011-12-02 | 2013-06-06 | Di Cara Danielle Marie | Antibodies against hgf - receptor and uses |
| US8900582B2 (en) | 2011-12-22 | 2014-12-02 | Samsung Electronics Co., Ltd. | Deimmunized anti c-Met humanized antibodies and uses thereof |
| WO2013130565A1 (en) * | 2012-02-29 | 2013-09-06 | The Brigham And Women's Hosptial, Inc. | Neutralizing antibody for epstein barr virus associated disease |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| EP2863946A4 (en) | 2012-06-21 | 2016-04-13 | Sorrento Therapeutics Inc | ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET |
| KR101938698B1 (ko) | 2012-07-23 | 2019-01-16 | 삼성전자주식회사 | Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도 |
| KR101938699B1 (ko) | 2012-07-23 | 2019-01-16 | 삼성전자주식회사 | Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US20140065655A1 (en) * | 2012-09-05 | 2014-03-06 | Scivax Corporation | Screening method for substance acting on maintenance of epithelial properties of cell |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| US20150259430A1 (en) | 2012-11-05 | 2015-09-17 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| WO2014074907A1 (en) * | 2012-11-09 | 2014-05-15 | Indi Molecular, Inc. | C-met-specific capture agents, compositions, and methods of using and making |
| KR101911048B1 (ko) | 2013-01-29 | 2018-10-24 | 삼성전자주식회사 | ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물 |
| HK1211235A1 (en) | 2013-02-22 | 2016-05-20 | 霍夫曼-拉罗奇有限公司 | Methods of treating cancer and preventing drug resistance |
| US9458245B2 (en) | 2013-03-06 | 2016-10-04 | Merrimack Pharmaceuticals, Inc. | ANTI-C-MET tandem Fc bispecific antibodies |
| AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| KR102049990B1 (ko) * | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| KR102139607B1 (ko) * | 2013-04-01 | 2020-07-30 | 삼성전자주식회사 | 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102089591B1 (ko) | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
| WO2015031626A1 (en) | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| WO2015031614A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| US9717715B2 (en) | 2013-11-15 | 2017-08-01 | Samsung Electronics Co., Ltd. | Method of combination therapy using an anti-C-Met antibody |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| KR20170005016A (ko) | 2014-05-23 | 2017-01-11 | 제넨테크, 인크. | MiT 바이오마커 및 그의 사용 방법 |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| KR102200274B1 (ko) | 2014-09-16 | 2021-01-08 | 심포젠 에이/에스 | 항-ｍｅｔ 항체 및 조성물 |
| US9796778B1 (en) | 2014-10-03 | 2017-10-24 | Academia Sinica | Antibodies against pathological forms of TDP-43 and uses thereof |
| WO2016053610A1 (en) * | 2014-10-03 | 2016-04-07 | Academia Sinica | Antibodies against pathological forms of tdp-43 and uses thereof |
| EP3221468B1 (en) * | 2014-11-20 | 2020-03-25 | Stichting Katholieke Universiteit | A novel auto-active and intracellular mutant of met |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| EP3233910B1 (en) | 2014-12-19 | 2019-12-11 | Ablynx N.V. | Cysteine linked nanobody dimers |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| US20180057595A1 (en) * | 2015-03-16 | 2018-03-01 | Celldex Therapeutics, Inc. | Anti-MET Antibodies and Methods of Use Thereof |
| JP6929786B2 (ja) | 2015-04-02 | 2021-09-01 | アブリンクス エン．ヴェー． | 強力な抗ｈｉｖ活性を有する二重特異性ｃｘｃｒ４−ｃｄ４ポリペプチド |
| TW201709932A (zh) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| WO2017062496A2 (en) * | 2015-10-05 | 2017-04-13 | University Of Virginia Patent Foundation | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer |
| EP3371223B1 (en) | 2015-11-03 | 2021-03-10 | Merck Patent GmbH | Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof |
| US11046782B2 (en) | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
| MX2018014175A (es) | 2016-05-17 | 2020-02-07 | Abbvie Biotherapeutics Inc | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. |
| AU2017292752B2 (en) * | 2016-07-06 | 2023-07-27 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
| US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| US20180230218A1 (en) | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| WO2019018538A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RECOMBINANT ANTIBODIES BINDING TO CD123 |
| KR102194025B1 (ko) | 2017-12-15 | 2020-12-22 | 경북대학교 산학협력단 | CD44v6에 결합하는 펩타이드 및 이의 용도 |
| WO2019117691A1 (ko) * | 2017-12-15 | 2019-06-20 | 경북대학교 산학협력단 | CD44v6에 결합하는 펩타이드 및 이의 용도 |
| US20210051929A1 (en) * | 2018-03-24 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| BR112020023846A2 (pt) | 2018-05-23 | 2021-04-13 | Adc Therapeutics Sa | Adjuvante molecular |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| CN109541221B (zh) * | 2018-10-24 | 2022-03-22 | 益善生物技术股份有限公司 | 一种c-Met特异性抗体、组合物及试剂盒 |
| CN115605491A (zh) | 2019-04-05 | 2023-01-13 | 刘扶东（Us） | 抗唾液酸酶的糖类、其制造方法及用途 |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| CN116075315B (zh) | 2020-05-08 | 2025-12-19 | 周美吟 | 嵌合流感疫苗 |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| CN116783220A (zh) * | 2020-12-16 | 2023-09-19 | 武汉友芝友生物制药股份有限公司 | 抗bcma抗体及其制备方法和应用 |
| CN112679614B (zh) * | 2021-01-15 | 2022-08-16 | 广东安普泽生物医药股份有限公司 | 用于特异性结合rankl靶向治疗药物的抗体及其用途 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CN112946279A (zh) * | 2021-03-17 | 2021-06-11 | 扬州大学 | 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法 |
| AU2022253888A1 (en) | 2021-04-06 | 2023-09-28 | AbbVie Manufacturing Management Unlimited Company | Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin |
| US12257298B2 (en) | 2021-04-12 | 2025-03-25 | Academia Sinica | Coronavirus vaccine |
| UY39743A (es) | 2021-04-29 | 2022-11-30 | Abbvie Inc | Conjugados de anticuerpo anti-c-met y fármaco |
| TW202334429A (zh) | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| CN120787235A (zh) * | 2021-12-27 | 2025-10-14 | 周美吟 | Sars-cov-2棘蛋白特异性抗体及其用途 |
| TW202434637A (zh) * | 2022-12-20 | 2024-09-01 | 美商翰森生物有限責任公司 | 抗體、抗原結合片段及其醫藥用途 |
| CA3268566A1 (en) | 2023-04-08 | 2024-10-17 | Rock Biomedical Inc. | METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES |
| WO2025025434A1 (zh) * | 2023-08-02 | 2025-02-06 | 百泰生物药业有限公司 | EGFR/c-Met双特异性抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2840250C2 (de) | 1978-09-15 | 1983-01-20 | Siemens AG, 1000 Berlin und 8000 München | Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| DE69800716T2 (de) * | 1997-04-14 | 2001-09-20 | Micromet Gesellschaft Fuer Biomedizinische Forschung Mbh | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| EP1485130A4 (en) * | 2002-02-21 | 2006-11-22 | Univ Duke | REAGENTS AND THERAPEUTIC METHODS OF AUTOIMMUNE DISEASES |
| CA2516236A1 (en) * | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| KR101412271B1 (ko) * | 2003-05-09 | 2014-06-25 | 듀크 유니버시티 | Ｃｄ２０-특이적 항체 및 이를 이용한 방법 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| CN1922208A (zh) | 2003-12-11 | 2007-02-28 | 健泰科生物技术公司 | 用于抑制c－met二聚化及活化的方法和组合物 |
| ME01803B (me) * | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| US20060094059A1 (en) | 2004-09-22 | 2006-05-04 | Odyssey Thera, Inc. | Methods for identifying new drug leads and new therapeutic uses for known drugs |
| KR101363120B1 (ko) * | 2005-02-10 | 2014-02-13 | 베일러 리서치 인스티튜트 | 항-인터페론 알파 모노클로날 항체 및 사용 방법 |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| RS54984B1 (sr) | 2005-07-18 | 2016-11-30 | Amgen Inc | Humana anti-b7rp1 neutrališuća antitela |
| JP5457671B2 (ja) | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用 |
| US8388958B2 (en) | 2006-02-06 | 2013-03-05 | Metheresis Translational Research Sa | Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| CN103183738B (zh) | 2006-03-30 | 2014-08-06 | 诺瓦提斯公司 | c-Met抗体的组合物和使用方法 |
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
-
2007
- 2007-07-12 EP EP07301231A patent/EP2014681A1/en not_active Withdrawn
-
2008
- 2008-07-10 NZ NZ599958A patent/NZ599958A/xx not_active IP Right Cessation
- 2008-07-10 DK DK08786050.8T patent/DK2188312T3/en active
- 2008-07-10 ES ES12183763.7T patent/ES2693542T3/es active Active
- 2008-07-10 RU RU2010104633/10A patent/RU2552161C2/ru active
- 2008-07-10 ES ES11162720.4T patent/ES2678495T3/es active Active
- 2008-07-10 US US12/440,571 patent/US8329173B2/en active Active
- 2008-07-10 EP EP08786050.8A patent/EP2188312B1/en active Active
- 2008-07-10 CN CN201310478511.XA patent/CN103509112B/zh active Active
- 2008-07-10 CN CN201310478556.7A patent/CN103509113B/zh active Active
- 2008-07-10 EP EP12183763.7A patent/EP2535357B1/en active Active
- 2008-07-10 HU HUE08786050A patent/HUE026026T2/en unknown
- 2008-07-10 CN CN201310073997.9A patent/CN103183739B/zh active Active
- 2008-07-10 BR BRPI0815564A patent/BRPI0815564B8/pt active IP Right Grant
- 2008-07-10 KR KR1020107003216A patent/KR101625234B1/ko active Active
- 2008-07-10 ES ES12183761.1T patent/ES2686693T3/es active Active
- 2008-07-10 JP JP2010515513A patent/JP5562844B2/ja active Active
- 2008-07-10 ES ES08786050.8T patent/ES2542059T3/es active Active
- 2008-07-10 KR KR1020157015922A patent/KR101719084B1/ko active Active
- 2008-07-10 MY MYPI2010000127A patent/MY158756A/en unknown
- 2008-07-10 EP EP12183761.1A patent/EP2535356B1/en active Active
- 2008-07-10 KR KR1020167002898A patent/KR101701685B1/ko active Active
- 2008-07-10 CA CA2888691A patent/CA2888691C/en active Active
- 2008-07-10 PL PL08786050T patent/PL2188312T3/pl unknown
- 2008-07-10 PT PT87860508T patent/PT2188312E/pt unknown
- 2008-07-10 RS RS20150560A patent/RS54197B1/sr unknown
- 2008-07-10 CL CL2008002015A patent/CL2008002015A1/es unknown
- 2008-07-10 SI SI200831467T patent/SI2188312T1/sl unknown
- 2008-07-10 EP EP11162718.8A patent/EP2415784B1/en active Active
- 2008-07-10 CA CA2981821A patent/CA2981821C/en active Active
- 2008-07-10 WO PCT/EP2008/059026 patent/WO2009007427A2/en not_active Ceased
- 2008-07-10 SG SG2012050837A patent/SG183015A1/en unknown
- 2008-07-10 CN CN200880024368.4A patent/CN101981054B/zh active Active
- 2008-07-10 ME MEP-2016-197A patent/ME02341B/me unknown
- 2008-07-10 EP EP11162720.4A patent/EP2415785B1/en active Active
- 2008-07-10 MX MX2014008274A patent/MX345391B/es unknown
- 2008-07-10 NZ NZ599959A patent/NZ599959A/xx unknown
- 2008-07-10 ES ES11162718.8T patent/ES2686335T3/es active Active
- 2008-07-10 AU AU2008274171A patent/AU2008274171B2/en active Active
- 2008-07-10 NZ NZ613716A patent/NZ613716A/en not_active IP Right Cessation
- 2008-07-10 MX MX2014007693A patent/MX353449B/es unknown
- 2008-07-10 NZ NZ583041A patent/NZ583041A/en unknown
- 2008-07-10 KR KR1020167002899A patent/KR101701686B1/ko active Active
- 2008-07-10 PA PA20088789201A patent/PA8789201A1/es unknown
- 2008-07-10 CA CA2982484A patent/CA2982484C/en active Active
- 2008-07-10 CA CA2694418A patent/CA2694418C/en active Active
- 2008-07-10 HR HRP20150887TT patent/HRP20150887T1/hr unknown
- 2008-07-11 TW TW103121603A patent/TWI592427B/zh active
- 2008-07-11 AR ARP080102991A patent/AR067517A1/es active IP Right Grant
- 2008-07-11 TW TW104114445A patent/TWI602830B/zh active
- 2008-07-11 TW TW097126356A patent/TWI549965B/zh active
- 2008-07-11 TW TW104114444A patent/TWI602829B/zh active
- 2008-07-12 SA SA08290423A patent/SA08290423B1/ar unknown
-
2010
- 2010-01-03 IL IL203114A patent/IL203114A/en active IP Right Grant
- 2010-01-08 TN TNP2010000016A patent/TN2010000016A1/fr unknown
- 2010-01-08 MX MX2013010752A patent/MX341012B/es unknown
- 2010-02-10 MA MA32608A patent/MA31977B1/fr unknown
- 2010-02-10 ZA ZA2010/00966A patent/ZA201000966B/en unknown
- 2010-02-12 CO CO10016035A patent/CO6170364A2/es active IP Right Grant
-
2012
- 2012-11-09 US US13/673,752 patent/US9107907B2/en active Active
- 2012-11-09 US US13/673,690 patent/US8871909B2/en active Active
- 2012-11-09 US US13/673,716 patent/US8871910B2/en active Active
- 2012-11-09 US US13/673,726 patent/US8889832B2/en active Active
- 2012-11-18 IL IL223109A patent/IL223109B/en active IP Right Grant
- 2012-11-18 IL IL223108A patent/IL223108B/en active IP Right Grant
- 2012-11-18 IL IL223106A patent/IL223106B/en active IP Right Grant
- 2012-11-18 IL IL223105A patent/IL223105B/en active IP Right Grant
-
2014
- 2014-01-06 JP JP2014000617A patent/JP5889924B2/ja active Active
- 2014-01-06 JP JP2014000616A patent/JP5889923B2/ja active Active
- 2014-01-06 JP JP2014000618A patent/JP5889925B2/ja active Active
-
2015
- 2015-03-17 US US14/660,046 patent/US20150252114A1/en not_active Abandoned
- 2015-08-04 CY CY20151100680T patent/CY1116608T1/el unknown
-
2017
- 2017-09-15 AR ARP170102560A patent/AR109535A2/es unknown
- 2017-09-15 AR ARP170102558A patent/AR109659A2/es unknown
- 2017-09-15 AR ARP170102559A patent/AR109660A2/es unknown
-
2018
- 2018-09-24 PH PH12018502039A patent/PH12018502039A1/en unknown
- 2018-09-24 PH PH12018502038A patent/PH12018502038A1/en unknown
- 2018-09-24 PH PH12018502040A patent/PH12018502040A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02341B (me) | Nova antitijela za inhibiciju c-met dimerizacije i njihova upotreba | |
| TWI853077B (zh) | 新型抗ｃｄ３９抗體 | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| CN110050000B (zh) | 含有TGF-β受体的融合蛋白及其医药用途 | |
| RU2011124751A (ru) | Антитело против смет | |
| TWI708788B (zh) | 雙特異性抗體 | |
| JP2010532982A5 (me) | ||
| Münz et al. | Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies | |
| RU2011115559A (ru) | Антитела к cxcr4 и их применение для лечения рака | |
| RU2010145063A (ru) | Новые антитела, используемые для лечения рака | |
| JP2023522229A (ja) | Ｎｅｃｔｉｎ－４に対する抗体及びその用途 | |
| CN103260646B (zh) | Notum蛋白调节剂和使用方法 | |
| US9534058B2 (en) | Anti-CD324 monoclonal antibodies and uses thereof | |
| JP2012504401A5 (me) | ||
| EP3743081A1 (en) | Antibodies specific to delta 1 chain of t cell receptor | |
| HRP20140502T1 (hr) | Humanizirana anti-cxcr4 antitijela za lijeäśenje karcinoma | |
| TWI865753B (zh) | 雙特異性抗體及其製造方法 | |
| JP2010509931A5 (me) | ||
| CN111378044A (zh) | 抗体融合蛋白、制备方法及其应用 | |
| KR101800774B1 (ko) | 암 진단 및 치료용 cd55 표적 항체 및 이의 용도 | |
| JPWO2020237173A5 (me) | ||
| JP2025524306A (ja) | Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体 | |
| CN105646712B (zh) | 单克隆抗体及其应用 | |
| CN118047867B (zh) | 一种抗bcma的纳米抗体、抗体及其应用 | |
| WO2024131835A1 (en) | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof |